ACADIA Pharmaceuticals Inc. · NASDAQ:ACAD
ACADIA Pharmaceuticals — Technical Presentation (March 2007)
10 slides from ACADIA Pharmaceuticals's technical presentation, Mar 19, 2007
Slide 1: ACP-103 Phase II Schizophrenia Co-Therapy Trial Top-Line Results
ACP-103 Phase II Schizophrenia Co-Therapy Trial Top-Line Results March 19, 2007 Creating the Next Generation of CNS Drugs
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation may contain forward-looking statements, including statements regarding our research and development programs and, in particular, our program for ACP-103 as a co-therapy for the treatment of schizophrenia and the benefits to be derived therefrom. Statement
Slide 3: Trial Highlights
Trial Highlights ACP-103 co-therapy arms demonstrated statistically significant efficacy – met primary endpoint ACP-103/risperidone showed significant efficacy enhancement vs. risperidone LD ACP-103/risperidone was as effective as risperidone HD Co-therapy with ACP-103 accelerated the onset of antip
Slide 4: Study Design
Study Design ACP-103 (20 mg) + risperidone (2 mg) Design: Schizophrenia, acute patients All patients n=423; Safety n=412; ITT n=376 6 week inpatient/outpatient trial Five-arm study, 42-day treatment Primary endpoint: PANSS reduction (after day 42 vs. baseline) risperidone (2 mg) + placebo risperidon
Slide 5: Co-Therapy ACP-103 + Risperidone
Co-Therapy ACP-103 + 2 mg Risperidone ACP-103/risperidone provided highly significant antipsychotic efficacy – met primary endpoint (p<0.0001) ACP-103/risperidone provided statistically significant enhancement of efficacy versus risperidone LD (p=0.01) Based on the 23.0 vs. 16.6 point improvement in
Slide 6: Accelerated Response to ACP-103 Co-Therapy
Accelerated Response to ACP-103 Co-Therapy Responders (defined as 20% PANSS reduction) ITT LOCF, n=376 80% 70% p<0.03 60% % Responders 50% 40% 30% p<0.008 20% 10% 0% Wk5 Wk4 Wk3 Wk2 Wk1 Wk6 ACP-103 + RIS LD RIS HD RIS LD
Slide 7: Co-Therapy ACP-103 + Haloperidol
Co-Therapy ACP-103 + Haloperidol 2 mg ACP-103/haloperidol provided highly significant antipsychotic efficacy – met primary endpoint (p<0.0001) ACP-103/haloperidol was similar in efficacy to haloperidol arm Faster onset of antipsychotic action after 2 weeks was observed in the ACP-103/haloperidol arm
Slide 8: Preliminary Safety Findings
Preliminary Safety Findings All treatments were generally safe and well tolerated Adverse events were comparable between arms – generally mild to moderate in severity The most commonly reported AEs were sedation, headache, and agitation 50% less weight gain in ACP-103/risperidone vs. risperidone HD
Slide 9: Summary
Summary Results confirm previous prediction of ACP-103 co-therapy advantages Demonstrated advantages: enhanced efficacy, faster onset of action, and improved side effect profile, including less weight gain Results suggest that ACP-103 co-therapy may offer a new and improved treatment paradigm
Slide 10: Creating the Next Generation of CNS Drugs
Creating the Next Generation of CNS Drugs
ACADIA Pharmaceuticals — Technical Presentation (March 2007) on 6ix